TCGA-78-7146-01A-11R-2039-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- MYC_TARGETS_V1+0.560
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.520
- PROTEIN_SECRETION+0.490
- UNFOLDED_PROTEIN_RESPONSE+0.460
- MTORC1_SIGNALING+0.410
- MITOTIC_SPINDLE+0.380
- INTERFERON_ALPHA_RESPONSE+0.360
- GLYCOLYSIS+0.350
Top 10 suppressed
- KRAS_SIGNALING_DN-0.380
- PANCREAS_BETA_CELLS-0.350
- COAGULATION-0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- HEDGEHOG_SIGNALING-0.210
- WNT_BETA_CATENIN_SIGNALING-0.200
- KRAS_SIGNALING_UP-0.170
- XENOBIOTIC_METABOLISM-0.160
- MYOGENESIS-0.150
- NOTCH_SIGNALING-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.871 |
| 2 | TCGA-78-7542-01A-21R-2066-07 | — | cohortA1 | 0.867 |
| 3 | SRR650153 | — | — | 0.861 |
| 4 | TCGA-05-4415-01A-22R-1858-07 | — | cohortA4 | 0.861 |
| 5 | TCGA-CV-7432-01A-11R-2132-07 | — | — | 0.860 |
| 6 | TCGA-CR-6493-01A-11R-1873-07 | — | — | 0.856 |
| 7 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.851 |
| 8 | SRR934964 | — | — | 0.842 |
| 9 | SRR8942952 | — | — | 0.841 |
| 10 | MNG1211 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.460 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |